Table 1.
Patients characteristics
| Variables | Treatment group (n = 33) | Control group (n = 35) | p-value |
|---|---|---|---|
| Age, median (range) | 59 (43-75) | 62 (41-78) | 0.74 |
| Sex, n | |||
| Male | 19 | 20 | |
| Female | 14 | 15 | 0.97 |
| ECOG PS, median (range) | 0 (0-1) | 0 (0-2) | 0.37 |
| Primary tumour location | |||
| Right | 11 | 11 | |
| Transverse | 1 | 2 | |
| Left | 18 | 19 | |
| rectum | 3 | 3 | 0.91 |
| Metastatic sites | |||
| Liver | 24 | 26 | |
| Lymph nodes | 7 | 8 | |
| Lung | 2 | 1 | 0.98 |
| Chemotherapy regimen | |||
| Folfiri + cetuximab | 32 | 0 | |
| Folfiri | 0 | 33 | |
| Folfox + cetuximab | 1 | 0 | 0.94 |
| Folfox | 0 | 2 | |
| Overall Best Response | |||
| CR | 2 | 1 | |
| PR | 14 | 15 | |
| SD | 6 | 9 | |
| PD | 11 | 10 | 0.36 |
| Treatment duration | |||
| months, median | 4.9 | 5.3 | 0.51 |
| PFS | |||
| Months, median | 5.7 | 5.4 | 0.52 |
Abbreviations: NS: non significant, ECOG PS: Eastern Cooperative Oncology Group Performance Status.